This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LIU, L. Articles by SHERINS, R. J. Search for Related Content PubMed PubMed Citation Articles by LIU, L. Articles by SHERINS, R. J.

Two-Year Comparison of Testicular Responses to Pulsatile Gonadotropin-Releasing Hormone and Exogenous Gonadotropins From the Inception of Therapy in Men With Isolated Hypogonadotropic Hypogonadism

Developmental Endocrinology Branch, National Institute of Child Health and Human Development, and the Intramural Research Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: Linda Liu, M.D., National Institutes of Health, Building 10, Room 10N-262, 9000 Rockville Pike, Bethesda, Maryland 20892.

Men with the complete form of isolated hypogonadotropic hypogonadism (initial mean testes volume <4 mL) require 2 or more yr of exogenous gonadotropin therapy combining hCG and human menopausal gonadotropin (hMG) to achieve maximal, but subnormal, testis size and sperm output. To test whether pulsatile GnRH therapy, which more closely mimicks normal hormonal stimulation, would accelerate or further augment testicular growth, hasten the onset of sperm production, and/or increase sperm output more than occurs during conventional exogenous gonadotropin therapy, we administered either hCG/hMG or GnRH from the inception of therapy to 2 comparable groups of men with complete IHH (initial testicular volume, <4 mL) and compared their testicular responses during the first 2 hr of therapy. Five men were treated with pulsatile GnRH in doses of 143–714 ng/kg every 2 h, sc, while 11 other men received hCG (2000 IU) and hMG (75 IU FSH and 75 IU LH) im 3 times/week.

In the GnRH-treated men, the mean plasma total and free testosterone levels during therapy rose to within the normal range, but were significantly lower (P < 0.01 and P < 0.02, respectively) than those in the hCG/hMG-treated men. The mean plasma estradiol concentrations during therapy were within the high normal range and were similar in the two groups. The mean plasma FSH levels achieved in the GnRH-treated men were significantly (P < 0.01) and 1.3- to 3.2-fold higher than those in the hCG/hMG-treated men. The mean testicular size achieved in the GnRH-treated men was not significantly different from that in the hCG/hMG-treated men (P = 0.08); the mean testicular volumes after 2 yr were 4.8- and 4.3-fold the pretreatment values in the GnRH and hCG/hMG groups, respectively.

After 12 months of therapy, sperm production had occurred in one man in the GnRH group and in no subject in the hCG/ hMG group. After 24 months, two men in the GnRH group and eight men in the hCG/hMG group produced sperm. Thus, 40% of the GnRH-treated men and 80% of the hCG/hMG-treated men (P = NS) produced sperm after 2 yr of therapy. The sperm concentrations in all men were below 5 million/mL and were comparable in the two groups (P = NS).

These results suggest that pulsatile sc GnRH therapy for the first 2 yr does not accelerate or enhance testicular growth, hasten the onset of sperm production, or increase sperm output significantly compared to hCG/hMG therapy.

Received April 29, 1988.

This article has been cited by other articles:

				D. Madhukar and S. Rajender Hormonal Treatment of Male Infertility: Promises and Pitfalls J Androl, March 1, 2009; 30(2): 95 - 112. [Abstract] [Full Text] [PDF]

				E. M Delemarre, B. Felius, and H. A Delemarre-van de Waal Inducing puberty Eur. J. Endocrinol., December 1, 2008; 159(suppl_1): S9 - S15. [Abstract] [Full Text] [PDF]

				S. Bhasin Approach to the Infertile Man J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 1995 - 2004. [Abstract] [Full Text] [PDF]

				A. D. Coviello, A. M. Matsumoto, W. J. Bremner, K. L. Herbst, J. K. Amory, B. D. Anawalt, P. R. Sutton, W. W. Wright, T. R. Brown, X. Yan, et al. Low-Dose Human Chorionic Gonadotropin Maintains Intratesticular Testosterone in Normal Men with Testosterone-Induced Gonadotropin Suppression J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2595 - 2602. [Abstract] [Full Text] [PDF]

				I. Fahmy, A. Kamal, R. Shamloul, R. Mansour, G. Serour, and M. Aboulghar ICSI using testicular sperm in male hypogonadotrophic hypogonadism unresponsive to gonadotrophin therapy Hum. Reprod., July 1, 2004; 19(7): 1558 - 1561. [Abstract] [Full Text] [PDF]

				N. Pitteloud, F. J. Hayes, A. Dwyer, P. A. Boepple, H. Lee, and W. F. Crowley Jr. Predictors of Outcome of Long-Term GnRH Therapy in Men with Idiopathic Hypogonadotropic Hypogonadism J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4128 - 4136. [Abstract] [Full Text] [PDF]

				P. Y. Liu, V. J. Gebski, L. Turner, A. J. Conway, S. M. Wishart, and D. J. Handelsman Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men Hum. Reprod., March 1, 2002; 17(3): 625 - 633. [Abstract] [Full Text] [PDF]

				P. Y. Liu, L. Turner, D. Rushford, J. McDonald, H.W.G. Baker, A. J. Conway, and D. J. Handelsman Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men Hum. Reprod., June 1, 1999; 14(6): 1540 - 1545. [Abstract] [Full Text] [PDF]